With Factor VIIa Tie-up, Wyeth And Catalyst Look To Take On Novo Nordisk
This article was originally published in The Pink Sheet Daily
In their second collaboration, the pharma and the biotech aim to develop a longer-acting, more potent hemophilia drug.
You may also be interested in...
The collaboration involves discovery work on undisclosed targets in the autoimmune and inflammatory disease areas.
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.